SpyGlass Pharma completed a $172.5 million IPO in February 2026 and reported positive 12-month Phase 1/2 trial results for its BIM-IOL System, showing sustained intraocular pressure control and elimination of eye drops for 97% of patients. Phase 3 trials are underway with full enrollment expected in 2027. The company expects its cash to fund operations through 2028 and plans to initiate a first-in-human trial for its BIM-DRS device later in 2026, aiming to offer long-term, eye drop-free glaucoma treatment for cataract surgery patients.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
